| Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer G Von Minckwitz, M Procter, E De Azambuja, D Zardavas, M Benyunes, ... New England Journal of Medicine 377 (2), 122-131, 2017 | 1449 | 2017 |
| Clinical management of breast cancer heterogeneity D Zardavas, A Irrthum, C Swanton, M Piccart Nature reviews Clinical oncology 12 (7), 381-394, 2015 | 548 | 2015 |
| Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma DF Bajorin, JA Witjes, JE Gschwend, M Schenker, BP Valderrama, ... New England Journal of Medicine 384 (22), 2102-2114, 2021 | 511 | 2021 |
| Luminal B breast cancer: molecular characterization, clinical management, and future perspectives F Ades, D Zardavas, I Bozovic-Spasojevic, L Pugliano, D Fumagalli, ... Journal of clinical oncology 32 (25), 2794-2803, 2014 | 452 | 2014 |
| Progress in adjuvant systemic therapy for breast cancer NF Pondé, D Zardavas, M Piccart Nature reviews Clinical oncology 16 (1), 27-44, 2019 | 228 | 2019 |
| Emerging targeted agents in metastatic breast cancer D Zardavas, J Baselga, M Piccart Nature reviews Clinical oncology 10 (4), 191-210, 2013 | 221 | 2013 |
| The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers in breast cancer clinical … PI Gonzalez‐Ericsson, ES Stovgaard, LF Sua, E Reisenbichler, Z Kos, ... The Journal of pathology 250 (5), 667-684, 2020 | 165 | 2020 |
| Endocrine treatment in breast cancer: Cure, resistance and beyond K Tryfonidis, D Zardavas, BS Katzenellenbogen, M Piccart Cancer treatment reviews 50, 68-81, 2016 | 151 | 2016 |
| Role of troponins I and T and N-terminal prohormone of brain natriuretic peptide in monitoring cardiac safety of patients with early-stage human epidermal growth factor … D Zardavas, TM Suter, DJ Van Veldhuisen, J Steinseifer, J Noe, S Lauer, ... J Clin Oncol 35 (8), 878-884, 2017 | 146 | 2017 |
| PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data D Zardavas, WA Phillips, S Loi Breast cancer research 16, 1-10, 2014 | 132 | 2014 |
| Efficacy of adjuvant trastuzumab for patients with human epidermal growth factor receptor 2–positive early breast cancer and tumors≤ 2 cm: a meta-analysis of the randomized … CC O'Sullivan, I Bradbury, C Campbell, M Spielmann, EA Perez, ... Journal of Clinical Oncology 33 (24), 2600, 2015 | 131 | 2015 |
| The prognostic role of androgen receptor in patients with early-stage breast cancer: a meta-analysis of clinical and gene expression data I Bozovic-Spasojevic, D Zardavas, S Brohée, L Ameye, D Fumagalli, ... Clinical Cancer Research 23 (11), 2702-2712, 2017 | 124 | 2017 |
| Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data D Zardavas, L Te Marvelde, RL Milne, D Fumagalli, G Fountzilas, ... Journal of Clinical Oncology 36 (10), 981-990, 2018 | 112 | 2018 |
| Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial M Colleoni, W Luo, P Karlsson, J Chirgwin, S Aebi, G Jerusalem, P Neven, ... The lancet oncology 19 (1), 127-138, 2018 | 112 | 2018 |
| Health-related quality of life in locally advanced and metastatic breast cancer: methodological and clinical issues in randomised controlled trials I Ghislain, E Zikos, C Coens, C Quinten, V Balta, K Tryfonidis, M Piccart, ... The Lancet Oncology 17 (7), e294-e304, 2016 | 102 | 2016 |
| The AURORA initiative for metastatic breast cancer D Zardavas, M Maetens, A Irrthum, T Goulioti, K Engelen, D Fumagalli, ... British journal of cancer 111 (10), 1881-1887, 2014 | 100 | 2014 |
| Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI … C Saura, D Hlauschek, M Oliveira, D Zardavas, A Jallitsch-Halper, ... The Lancet Oncology 20 (9), 1226-1238, 2019 | 98 | 2019 |
| Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: a randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE) S Loibl, L de la Pena, V Nekljudova, D Zardavas, S Michiels, C Denkert, ... European journal of cancer 85, 133-145, 2017 | 98 | 2017 |
| The past and future of breast cancer treatment—from the papyrus to individualised treatment approaches F Ades, K Tryfonidis, D Zardavas ecancermedicalscience 11, 2017 | 82 | 2017 |
| Neoadjuvant therapy for breast cancer D Zardavas, M Piccart Annual review of medicine 66, 31-48, 2015 | 74 | 2015 |
Giuseppe VialeUniversità di Milano e Istituto Europeo di OncologiaEmail confirmado em ieo.it
